(AUPH) Aurinia Pharmaceuticals - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.898m USD | Total Return: 92.2% in 12m

Stock Autoimmune Therapies, Lupus Treatment, Drug Development
Total Rating 62
Risk 30
Buy Signal 1.19
Biotechnology +0.2
Biotechnology +1.0
Market Cap: 1,898m
Avg Trading Vol: 15.2M USD
ATR: 3.98%
Peers RS (IBD): 61.8
Risk 5d forecast
Volatility53.6%
Rel. Tail Risk-17.2%
Reward TTM
Sharpe Ratio1.49
Alpha64.90
Character TTM
Beta0.681
Beta Downside2.173
Drawdowns 3y
Max DD60.80%
CAGR/Max DD0.22
EPS (Earnings per Share) EPS (Earnings per Share) of AUPH over the last years for every Quarter: "2021-03": -0.4, "2021-06": -0.37, "2021-09": -0.39, "2021-12": -0.25, "2022-03": -0.27, "2022-06": -0.25, "2022-09": -0.06, "2022-12": -0.18, "2023-03": -0.18, "2023-06": -0.08, "2023-09": -0.09, "2023-12": -0.19, "2024-03": -0.03, "2024-06": 0.01, "2024-09": 0.1, "2024-12": 0.01, "2025-03": 0.16, "2025-06": 0.16, "2025-09": 0.23, "2025-12": 1.53, "2026-03": 0,
EPS CAGR: 122.98%
EPS Trend: 63.8%
Last SUE: -0.34
Qual. Beats: 0
Revenue Revenue of AUPH over the last years for every Quarter: 2021-03: 0.914, 2021-06: 6.62, 2021-09: 14.667, 2021-12: 23.404, 2022-03: 21.625, 2022-06: 28.191, 2022-09: 55.779, 2022-12: 28.435, 2023-03: 34.409, 2023-06: 41.494, 2023-09: 54.515, 2023-12: 45.095, 2024-03: 50.303, 2024-06: 57.192, 2024-09: 67.771, 2024-12: 59.867, 2025-03: 62.465, 2025-06: 70.008, 2025-09: 73.468, 2025-12: 77.114, 2026-03: null,
Rev. CAGR: 40.36%
Rev. Trend: 86.4%
Last SUE: 0.69
Qual. Beats: 0
Description: AUPH Aurinia Pharmaceuticals March 05, 2026

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on autoimmune disease therapies. The biotechnology sector is characterized by extensive research and development pipelines.

The companys primary commercial product is LUPKYNIS (voclosporin), an oral treatment for active lupus nephritis. Their business model involves developing and commercializing specialized treatments for conditions with unmet medical needs.

Aurinia is also developing AUR200 for autoimmune diseases and has a collaboration with Otsuka Pharmaceutical Co., Ltd. For more detailed analysis, consider exploring ValueRay.

Headlines to Watch Out For
  • LUPKYNIS sales growth drives revenue
  • Lupus nephritis treatment market competition intensifies
  • Clinical trial success for aritinercept expands pipeline
  • Regulatory approval process for new drugs impacts timelines
Piotroski VR‑10 (Strict, 0-10) 6.5
Net Income: 287.2m TTM > 0 and > 6% of Revenue
FCF/TA: 0.18 > 0.02 and ΔFCF/TA 9.86 > 1.0
NWC/Revenue: 140.7% < 20% (prev 148.4%; Δ -7.66% < -1%)
CFO/TA 0.18 > 3% & CFO 134.6m > Net Income 287.2m
Net Debt (-5.40m) to EBITDA (142.3m): -0.04 < 3
Current Ratio: 5.25 > 1.5 & < 3
Outstanding Shares: last quarter (138.7m) vs 12m ago -6.08% < -2%
Gross Margin: 88.46% > 18% (prev 0.88%; Δ 8.76k% > 0.5%)
Asset Turnover: 43.47% > 50% (prev 42.70%; Δ 0.77% > 0%)
Interest Coverage Ratio: 12.54 > 6 (EBITDA TTM 142.3m / Interest Expense TTM 9.80m)
Altman Z'' 4.83
A: 0.53 (Total Current Assets 492.0m - Total Current Liabilities 93.7m) / Total Assets 751.6m
B: -0.86 (Retained Earnings -649.4m / Total Assets 751.6m)
C: 0.19 (EBIT TTM 122.9m / Avg Total Assets 651.1m)
D: 2.76 (Book Value of Equity 470.1m / Total Liabilities 170.3m)
Altman-Z'' Score: 4.83 = AA
Beneish M 1.00
DSRI: 0.94 (Receivables 41.5m/36.5m, Revenue 283.1m/235.1m)
GMI: 0.99 (GM 88.46% / 87.99%)
AQI: 25.48 (AQ_t 0.24 / AQ_t-1 0.01)
SGI: 1.20 (Revenue 283.1m / 235.1m)
TATA: 0.20 (NI 287.2m - CFO 134.6m) / TA 751.6m)
Beneish M-Score: 11.79 (Cap -4..+1) = D
What is the price of AUPH shares? As of April 02, 2026, the stock is trading at USD 14.82 with a total of 1,462,642 shares traded.
Over the past week, the price has changed by +7.65%, over one month by +8.87%, over three months by +0.78% and over the past year by +92.17%.
Is AUPH a buy, sell or hold? Aurinia Pharmaceuticals has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy AUPH.
  • StrongBuy: 3
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the AUPH price?
ISSUER TARGET UP/DOWN
Wallstreet Target Price 17 14.7%
Analysts Target Price 17 14.7%
AUPH Fundamental Data Overview March 30, 2026
P/E Trailing = 6.8937
P/E Forward = 20.4499
P/S = 6.7036
P/B = 3.2114
Revenue TTM = 283.1m USD
EBIT TTM = 122.9m USD
EBITDA TTM = 142.3m USD
Long Term Debt = 74.8m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 17.6m USD (from shortTermDebt, last quarter)
Debt = 74.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -5.40m USD (from netDebt column, last quarter)
Enterprise Value = 1.57b USD (1.90b + Debt 74.8m - CCE 398.0m)
Interest Coverage Ratio = 12.54 (Ebit TTM 122.9m / Interest Expense TTM 9.80m)
EV/FCF = 11.72x (Enterprise Value 1.57b / FCF TTM 134.3m)
FCF Yield = 8.53% (FCF TTM 134.3m / Enterprise Value 1.57b)
FCF Margin = 47.45% (FCF TTM 134.3m / Revenue TTM 283.1m)
Net Margin = 101.5% (Net Income TTM 287.2m / Revenue TTM 283.1m)
Gross Margin = 88.46% ((Revenue TTM 283.1m - Cost of Revenue TTM 32.7m) / Revenue TTM)
Gross Margin QoQ = 89.01% (prev 88.42%)
Tobins Q-Ratio = 2.09 (Enterprise Value 1.57b / Total Assets 751.6m)
Interest Expense / Debt = 8.71% (Interest Expense 6.51m / Debt 74.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = 97.1m (EBIT 122.9m * (1 - 21.00%))
Current Ratio = 5.25 (Total Current Assets 492.0m / Total Current Liabilities 93.7m)
Debt / Equity = 0.13 (Debt 74.8m / totalStockholderEquity, last quarter 581.3m)
Debt / EBITDA = -0.04 (Net Debt -5.40m / EBITDA 142.3m)
Debt / FCF = -0.04 (Net Debt -5.40m / FCF TTM 134.3m)
Total Stockholder Equity = 408.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 44.11% (Net Income 287.2m / Total Assets 751.6m)
RoE = 70.37% (Net Income TTM 287.2m / Total Stockholder Equity 408.1m)
RoCE = 25.44% (EBIT 122.9m / Capital Employed (Equity 408.1m + L.T.Debt 74.8m))
RoIC = 23.78% (NOPAT 97.1m / Invested Capital 408.1m)
WACC = 8.32% (E(1.90b)/V(1.97b) * Re(8.38%) + D(74.8m)/V(1.97b) * Rd(8.71%) * (1-Tc(0.21)))
Discount Rate = 8.38% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.80%
[DCF] Terminal Value 69.21% ; FCFF base≈98.2m ; Y1≈64.5m ; Y5≈29.5m
[DCF] Fair Price = 4.20 (EV 552.8m - Net Debt -5.40m = Equity 558.2m / Shares 133.0m; r=8.32% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 63.81 | EPS CAGR: 123.0% | SUE: -0.34 | # QB: 0
Revenue Correlation: 86.44 | Revenue CAGR: 40.36% | SUE: 0.69 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.22 | Chg7d=+0.017 | Chg30d=+0.017 | Revisions Net=-1 | Analysts=2
EPS current Year (2026-12-31): EPS=0.83 | Chg7d=-0.100 | Chg30d=-0.100 | Revisions Net=-1 | Growth EPS=-59.7% | Growth Revenue=+15.2%
EPS next Year (2027-12-31): EPS=0.83 | Chg7d=-0.235 | Chg30d=-0.235 | Revisions Net=-1 | Growth EPS=+0.0% | Growth Revenue=+17.6%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = -6.1% (Discount Rate 8.4% - Earnings Yield 14.5%)
[Growth] Growth Spread = +21.6% (Analyst 15.5% - Implied -6.1%)
Additional Sources for AUPH Stock Fund Manager Positions: Dataroma · Stockcircle